Remedi recorded 2025 full-year revenue of KRW 14.6 billion, operating profit of KRW 2.8 billion and net income of KRW 5.1 billion. Revenue rose 8.8% from KRW 13.4 billion in 2024, and operating profit rose 191.3% from KRW 900 million in 2024.
The company posted an operating loss of KRW 2.3 billion in 2023 before returning to profit in 2024, and the profit margin widened further in 2025. In the cumulative DART filing for the first nine months of 2026, revenue was KRW 3.8 billion, up 139.4% year on year.
Operating profit for the same period was KRW 281 million, a swing to profit, while the net loss was KRW 364 million, a swing to loss. Operating profit and net income therefore moved in different directions over the period.
At the IPO, the company presented a 2026 revenue forecast of KRW 24.2 billion, and the cumulative sales in the filing equal about 16% of that figure. The share price has been volatile since the July 2026 listing.
According to AlphaSquare, the 52-week high was KRW 34,650 and the low was KRW 6,980, and the close on September 29, 2026 was KRW 19,760, down 14.83%.
According to Daum Finance, the close on October 29, 2026 was KRW 14,070, and the current price is KRW 10,040, up 1.72% on the day, with a market capitalization of KRW 76.6 billion.